Pharmaceutical company Amneal Pharmaceuticals Inc (NYSE:AMRX) reported on Friday the receipt of the Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for the generic Fluphenazine Hydrochloride Tablets USP in 1mg, 2.5mg, 5mg and 10mg for treatment of schizophrenia.
The company added that the Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia.
Effective immediately, the company has initiated commercialization activities of generic Fluphenazine Hydrochloride across all dosages.
In conjunction, the US annual sales for Fluphenazine Hydrochloride Tablets for the 12 months ended May 2020 were approximately USD143m, according to IQVIA, a leading healthcare data and analytics provider.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream